These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 9762189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [Abstract] [Full Text] [Related]

  • 8. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 May; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

  • 9. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A, Evangelista A, Mariani A, Bersani M, Bonato C, Basilico M, Montorsi M, Beretta E.
    Int J Pancreatol; 1988 May; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [Abstract] [Full Text] [Related]

  • 10. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M, Metzger U, Joller H, Largiadèr F.
    Schweiz Med Wochenschr; 1988 Jun 18; 118(24):924-9. PubMed ID: 2456610
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb 18; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 18. [Differential diagnostic evaluation of chronic pancreatitis in relation to pancreatic cancer based on clinical, laboratory chemical and diagnostic parameters. Studies of 174 patients in 10 years].
    Gronen G, Dombrowski H, Adler G, Lorenz-Meyer H.
    Z Gastroenterol; 1986 Aug 18; 24(8):416-25. PubMed ID: 3532595
    [Abstract] [Full Text] [Related]

  • 19. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F, Büchler M, Schenkluhn B, Beger HG.
    Dtsch Med Wochenschr; 1984 Dec 07; 109(49):1869-73. PubMed ID: 6209082
    [Abstract] [Full Text] [Related]

  • 20. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.
    Pancreas; 2007 May 07; 34(4):436-43. PubMed ID: 17446843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.